Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study.

Delmas, P D; Balena, R; Confravreux, E; Hardouin, C; Hardy, P; Bremond, A

Delmas, P D; Balena, R; Confravreux, E; Hardouin, C; Hardy, P; Bremond, A.

Affiliation

Delmas PD; INSERM Research Unit 403, Hôpital E. Herriot, Lyon, France.

J Clin Oncol ; 15(3): 955-62, 1997 Mar.

Article in En | MEDLINE | ID: mdl-9060533

Subject(s)

Breast Neoplasms/drug therapy; Calcium Channel Blockers/therapeutic use; Etidronic Acid/analogs & derivatives; Osteoporosis, Postmenopausal/prevention & control; Adult; Antineoplastic Agents, Hormonal/administration & dosage; Antineoplastic Agents, Hormonal/therapeutic use; Bone Density/drug effects; Calcium Channel Blockers/adverse effects; Double-Blind Method; Drug Administration Schedule; Etidronic Acid/adverse effects; Etidronic Acid/therapeutic use; Female; Femur Neck/drug effects; Humans; Lumbar Vertebrae/drug effects; Lumbar Vertebrae/physiopathology; Middle Aged; Osteoporosis, Postmenopausal/chemically induced; Osteoporosis, Postmenopausal/physiopathology; Risedronic Acid; Tamoxifen/administration & dosage; Tamoxifen/therapeutic use

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Calcium Channel Blockers / Osteoporosis, Postmenopausal / Etidronic Acid Type of study: Clinical_trials Limits: Adult / Female / Humans / Middle aged Language: En Journal: J Clin Oncol Year: 1997 Type: Article Affiliation country: France

Search on Google

XML

PubMed Links